Latest Period
Q1 2026
Security Snapshot
SELLAS Life Sciences Group, Inc. - Common Stock (SLS) Institutional Ownership
CUSIP: 81642T209
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
159
Shares (Excl. Options)
53,960,817
Price
$4.23
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- SLS on Nasdaq
- Shares outstanding
- 178,475,456
- Price per share
- $4.67
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 53,960,817
- Total reported value
- $228,424,280
- % of total 13F portfolios
- 0%
- Share change
- +16,598,734
- Value change
- +$70,797,153
- Number of holders
- 159
- Price from insider filings
- $4.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- SLS - SELLAS Life Sciences Group, Inc. - Common Stock is tracked under CUSIP 81642T209.
- 159 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 112 to 159 between Q4 2025 and Q1 2026.
- Reported value moved from $133,935,339 to $228,424,280.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 159 institutions filings for Q1 2026.
Security key
81642T209
Latest holder period
Q1 2026
13F holders
159
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
SLS full holder history
SELLAS Life Sciences Group, Inc. SEC filings
SELLAS Life Sciences Group, Inc. company facts
SELLAS Life Sciences Group, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 81642T209:
Significant Owners of SELLAS Life Sciences Group, Inc. - Common Stock (SLS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.8% | +28% | $51,336,680 | +$27,281,152 | 12,136,331 | +113% | BlackRock, Inc. | 31 Mar 2026 |
| Anson Funds Management LP | 4.9% | -13% | $31,046,889 | +$6,010,196 | 7,481,178 | +24% | Anson Funds Management LP | 31 Dec 2025 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 3.7% | $24,560,261 | 6,514,658 | Highbridge Capital Management, LLC | 31 Dec 2025 |
As of 31 Mar 2026, 159 institutional investors reported holding 53,960,817 shares of SELLAS Life Sciences Group, Inc. - Common Stock (SLS). This represents 30% of the company’s total 178,475,456 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of SELLAS Life Sciences Group, Inc. - Common Stock (SLS) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6.8% | 12,198,410 | +62% | 0% | $51,599,273 |
| STATE STREET CORP | 4.7% | 8,396,356 | +284% | 0% | $35,516,586 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 7,525,929 | 0% | 0% | $31,834,680 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 3,912,606 | +27% | 0% | $16,554,768 |
| MARSHALL WACE, LLP | 1.1% | 2,037,162 | +52% | 0.01% | $8,617,196 |
| JONES FINANCIAL COMPANIES LLLP | 0.94% | 1,675,077 | +290% | 0% | $7,311,711 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.82% | 1,462,806 | 0% | 0% | $6,187,669 |
| MORGAN STANLEY | 0.75% | 1,336,293 | +50% | 0% | $5,652,520 |
| NORTHERN TRUST CORP | 0.71% | 1,275,984 | +37% | 0% | $5,397,412 |
| VANGUARD FIDUCIARY TRUST CO | 0.67% | 1,202,839 | 0% | 0% | $5,088,009 |
| DAGCO, INC. | 0.58% | 1,028,780 | +78% | 0.94% | $4,351,740 |
| UBS Group AG | 0.42% | 745,419 | +1430% | 0% | $3,153,123 |
| Invesco Ltd. | 0.39% | 698,080 | +1210% | 0% | $2,952,878 |
| Nuveen, LLC | 0.38% | 670,974 | -34% | 0% | $2,838,220 |
| BANK OF AMERICA CORP /DE/ | 0.36% | 641,683 | +536% | 0% | $2,714,320 |
| GOLDMAN SACHS GROUP INC | 0.31% | 555,913 | +35% | 0% | $2,351,512 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.27% | 480,604 | +18% | 0% | $2,032,955 |
| Bank of New York Mellon Corp | 0.27% | 478,366 | +87% | 0% | $2,023,488 |
| TWO SIGMA INVESTMENTS, LP | 0.23% | 403,165 | -63% | 0% | $1,705,388 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.22% | 397,056 | +14% | 0% | $1,679,547 |
| Everhart Financial Group, Inc. | 0.2% | 364,397 | -22% | 0.13% | $1,541,399 |
| Opus Capital Group, LLC | 0.19% | 346,452 | +9.3% | 0.16% | $1,465,000 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.19% | 344,778 | 0% | $1,458,411 | |
| VISION FINANCIAL MARKETS LLC | 0.17% | 304,400 | 1.3% | $1,287,612 | |
| SIMPLEX TRADING, LLC | 0.17% | 295,162 | 0.04% | $1,248,535 |
Institutional Holders of SELLAS Life Sciences Group, Inc. - Common Stock (SLS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 53,960,817 | $228,424,280 | +$70,797,153 | $4.23 | 159 |
| 2025 Q4 | 35,512,660 | $133,935,339 | +$23,683,756 | $3.77 | 112 |
| 2025 Q3 | 32,917,301 | $53,012,951 | +$9,796,863 | $1.61 | 92 |
| 2025 Q2 | 26,771,579 | $58,629,839 | +$27,498,028 | $2.19 | 78 |
| 2025 Q1 | 14,287,843 | $15,431,614 | +$8,743,246 | $1.08 | 43 |
| 2024 Q4 | 6,195,241 | $6,443,955 | +$751,049 | $1.04 | 29 |
| 2024 Q3 | 5,385,570 | $6,729,539 | +$1,661,405 | $1.25 | 30 |
| 2024 Q2 | 4,056,846 | $4,828,846 | -$3,466,325 | $1.19 | 29 |
| 2024 Q1 | 7,717,105 | $7,794,727 | +$4,207,509 | $1.01 | 27 |
| 2023 Q4 | 3,493,044 | $3,702,505 | +$352,826 | $1.06 | 29 |
| 2023 Q3 | 2,751,676 | $4,512,830 | -$594,241 | $1.64 | 25 |
| 2023 Q2 | 3,114,137 | $4,889,035 | +$175,383 | $1.57 | 22 |
| 2023 Q1 | 2,996,127 | $4,284,993 | +$1,438,716 | $1.43 | 20 |
| 2022 Q4 | 1,889,269 | $4,456,259 | +$91,291 | $2.36 | 27 |
| 2022 Q3 | 2,186,943 | $4,418,000 | -$1,738,313 | $2.02 | 25 |
| 2022 Q2 | 2,979,307 | $6,641,000 | +$1,671,317 | $2.23 | 23 |
| 2022 Q1 | 1,688,629 | $11,276,000 | -$279,247 | $6.68 | 25 |
| 2021 Q4 | 1,733,782 | $9,586,000 | -$1,340,161 | $5.53 | 26 |
| 2021 Q3 | 1,859,470 | $17,100,000 | -$844,204 | $9.16 | 29 |
| 2021 Q2 | 1,897,926 | $21,282,000 | +$4,739,163 | $11.10 | 28 |
| 2021 Q1 | 1,552,743 | $13,246,990 | +$5,287,808 | $8.54 | 28 |
| 2020 Q4 | 925,075 | $5,374,000 | +$2,503,596 | $5.81 | 17 |
| 2020 Q3 | 616,674 | $1,633,000 | +$397,179 | $2.65 | 10 |
| 2020 Q2 | 455,904 | $1,335,000 | +$144,563 | $2.93 | 12 |
| 2020 Q1 | 415,637 | $720,000 | -$87,849 | $1.74 | 10 |
| 2019 Q4 | 389,002 | $1,672,000 | +$1,672,000 | $4.30 | 9 |